Murat Gokden
Concepts (342)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 14 | 2024 | 288 | 2.560 |
Why?
| Immunohistochemistry | 18 | 2024 | 978 | 1.610 |
Why?
| Central Nervous System Neoplasms | 4 | 2024 | 64 | 1.530 |
Why?
| Neurodegenerative Diseases | 2 | 2024 | 78 | 1.440 |
Why?
| Meningeal Neoplasms | 4 | 2024 | 52 | 1.410 |
Why?
| Brain | 7 | 2024 | 1328 | 1.310 |
Why?
| Meningioma | 4 | 2024 | 46 | 1.270 |
Why?
| RNA-Binding Protein EWS | 2 | 2024 | 14 | 1.180 |
Why?
| Ki-67 Antigen | 3 | 2024 | 57 | 1.130 |
Why?
| Pituitary Neoplasms | 3 | 2021 | 28 | 1.110 |
Why?
| Adenoma | 3 | 2021 | 110 | 1.030 |
Why?
| Fat Emulsions, Intravenous | 1 | 2024 | 12 | 0.940 |
Why?
| Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 36 | 0.910 |
Why?
| Carcinoma, Renal Cell | 5 | 2010 | 105 | 0.910 |
Why?
| Alzheimer Disease | 2 | 2024 | 317 | 0.830 |
Why?
| Neoplasm Recurrence, Local | 4 | 2024 | 613 | 0.820 |
Why?
| Humans | 67 | 2024 | 50208 | 0.780 |
Why?
| Central Nervous System | 2 | 2022 | 85 | 0.740 |
Why?
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 11 | 0.730 |
Why?
| Pathology, Surgical | 1 | 2020 | 18 | 0.730 |
Why?
| Dementia, Vascular | 1 | 2020 | 6 | 0.720 |
Why?
| Genes, myc | 1 | 2020 | 41 | 0.720 |
Why?
| Glioblastoma | 2 | 2021 | 93 | 0.710 |
Why?
| Biological Specimen Banks | 1 | 2020 | 21 | 0.710 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2020 | 106 | 0.700 |
Why?
| Nervous System Diseases | 1 | 2021 | 89 | 0.700 |
Why?
| Amyloidosis | 1 | 2020 | 81 | 0.690 |
Why?
| Cell Proliferation | 1 | 2024 | 1013 | 0.690 |
Why?
| Male | 38 | 2024 | 25399 | 0.670 |
Why?
| Kidney Neoplasms | 4 | 2010 | 176 | 0.670 |
Why?
| Cytochrome-c Oxidase Deficiency | 1 | 2018 | 3 | 0.650 |
Why?
| Electron Transport Complex IV | 1 | 2018 | 29 | 0.640 |
Why?
| Carcinoma, Papillary | 3 | 2015 | 49 | 0.640 |
Why?
| Optic Atrophy | 1 | 2018 | 17 | 0.630 |
Why?
| Spasms, Infantile | 1 | 2018 | 27 | 0.620 |
Why?
| Leukemia, Lymphoid | 1 | 2018 | 6 | 0.620 |
Why?
| Brain Edema | 1 | 2018 | 41 | 0.620 |
Why?
| Intracranial Embolism | 1 | 2018 | 27 | 0.610 |
Why?
| Solitary Fibrous Tumors | 1 | 2017 | 5 | 0.570 |
Why?
| Spinal Cord Neoplasms | 1 | 2017 | 14 | 0.570 |
Why?
| Female | 36 | 2024 | 26635 | 0.560 |
Why?
| Pinealoma | 1 | 2015 | 5 | 0.510 |
Why?
| Middle Aged | 24 | 2024 | 12206 | 0.500 |
Why?
| PAX2 Transcription Factor | 3 | 2010 | 22 | 0.480 |
Why?
| Adult | 25 | 2024 | 13324 | 0.470 |
Why?
| Aged | 15 | 2024 | 9405 | 0.470 |
Why?
| Glioma | 4 | 2019 | 79 | 0.460 |
Why?
| Ataxia | 2 | 2015 | 20 | 0.440 |
Why?
| Transcription Factors | 3 | 2024 | 564 | 0.440 |
Why?
| Diagnosis, Differential | 10 | 2020 | 1043 | 0.440 |
Why?
| Neoplasm Grading | 2 | 2024 | 123 | 0.410 |
Why?
| Chordoma | 2 | 2010 | 8 | 0.400 |
Why?
| Fatal Outcome | 4 | 2020 | 195 | 0.360 |
Why?
| Encephalitis | 3 | 2016 | 41 | 0.350 |
Why?
| Hematologic Neoplasms | 2 | 2023 | 99 | 0.350 |
Why?
| Craniopharyngioma | 1 | 2009 | 11 | 0.330 |
Why?
| Neoplasm Metastasis | 4 | 2019 | 236 | 0.320 |
Why?
| Mutation | 5 | 2020 | 1294 | 0.320 |
Why?
| Neurofibromatosis 1 | 2 | 2019 | 33 | 0.320 |
Why?
| Fragile X Syndrome | 1 | 2008 | 4 | 0.320 |
Why?
| Peripheral Nervous System | 1 | 2008 | 15 | 0.310 |
Why?
| Neuroectodermal Tumors, Primitive | 1 | 2008 | 4 | 0.310 |
Why?
| Young Adult | 11 | 2024 | 3981 | 0.300 |
Why?
| Chondrosarcoma | 1 | 2007 | 11 | 0.300 |
Why?
| Skull Base Neoplasms | 1 | 2007 | 21 | 0.300 |
Why?
| Prenatal Diagnosis | 1 | 2008 | 105 | 0.290 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2008 | 155 | 0.290 |
Why?
| Radiotherapy | 2 | 2020 | 127 | 0.290 |
Why?
| Neoplasms | 2 | 2015 | 1249 | 0.280 |
Why?
| Melanoma | 3 | 2020 | 290 | 0.280 |
Why?
| Gene Rearrangement | 2 | 2024 | 74 | 0.280 |
Why?
| Liver Neoplasms | 3 | 2005 | 328 | 0.280 |
Why?
| Child | 13 | 2024 | 6851 | 0.280 |
Why?
| In Situ Hybridization, Fluorescence | 3 | 2024 | 259 | 0.280 |
Why?
| Adenoma, Oxyphilic | 1 | 2006 | 11 | 0.270 |
Why?
| Infant | 4 | 2024 | 3563 | 0.270 |
Why?
| Syndecan-1 | 1 | 2006 | 72 | 0.270 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2024 | 4 | 0.270 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 36 | 0.260 |
Why?
| Neurosurgical Procedures | 3 | 2015 | 121 | 0.250 |
Why?
| Magnetic Resonance Imaging | 7 | 2020 | 1541 | 0.250 |
Why?
| Skin Neoplasms | 3 | 2020 | 492 | 0.250 |
Why?
| Adolescent | 12 | 2024 | 6390 | 0.250 |
Why?
| Supratentorial Neoplasms | 1 | 2024 | 4 | 0.240 |
Why?
| Forensic Pathology | 1 | 2024 | 8 | 0.240 |
Why?
| Mitotic Index | 1 | 2024 | 8 | 0.240 |
Why?
| Rhabdoid Tumor | 1 | 2024 | 11 | 0.240 |
Why?
| Histiocytoma, Malignant Fibrous | 1 | 2024 | 1 | 0.230 |
Why?
| Tissue Banks | 1 | 2024 | 8 | 0.230 |
Why?
| Staining and Labeling | 1 | 2024 | 97 | 0.230 |
Why?
| Adrenergic beta-Antagonists | 1 | 2024 | 105 | 0.220 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 1 | 2023 | 23 | 0.220 |
Why?
| Nerve Sheath Neoplasms | 2 | 2015 | 20 | 0.210 |
Why?
| Nuclear Proteins | 1 | 2024 | 243 | 0.210 |
Why?
| DNA Helicases | 1 | 2024 | 144 | 0.210 |
Why?
| Histiocytic Sarcoma | 1 | 2022 | 2 | 0.200 |
Why?
| Sensitivity and Specificity | 5 | 2010 | 863 | 0.200 |
Why?
| Neural Stem Cells | 1 | 2022 | 26 | 0.200 |
Why?
| STAT2 Transcription Factor | 1 | 2021 | 7 | 0.200 |
Why?
| Drug Overdose | 1 | 2024 | 163 | 0.200 |
Why?
| STAT1 Transcription Factor | 1 | 2021 | 26 | 0.200 |
Why?
| Li-Fraumeni Syndrome | 1 | 2021 | 13 | 0.200 |
Why?
| Treatment Outcome | 5 | 2020 | 5155 | 0.200 |
Why?
| Sella Turcica | 1 | 2021 | 7 | 0.190 |
Why?
| Amyloid | 1 | 2020 | 28 | 0.180 |
Why?
| Turkey | 1 | 2020 | 18 | 0.180 |
Why?
| Myopathies, Structural, Congenital | 1 | 2020 | 10 | 0.180 |
Why?
| Drug Therapy | 1 | 2020 | 46 | 0.180 |
Why?
| Phenotype | 2 | 2020 | 733 | 0.180 |
Why?
| Aged, 80 and over | 3 | 2020 | 3154 | 0.180 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2020 | 86 | 0.170 |
Why?
| Follow-Up Studies | 3 | 2020 | 2190 | 0.170 |
Why?
| Epidural Neoplasms | 1 | 2019 | 4 | 0.170 |
Why?
| Spinal Cord Compression | 1 | 2019 | 10 | 0.170 |
Why?
| Neurilemmoma | 1 | 2019 | 24 | 0.170 |
Why?
| Biopsy | 3 | 2017 | 590 | 0.170 |
Why?
| Telomere Homeostasis | 1 | 2019 | 10 | 0.170 |
Why?
| Predictive Value of Tests | 4 | 2017 | 905 | 0.170 |
Why?
| Paranasal Sinus Neoplasms | 1 | 2019 | 21 | 0.170 |
Why?
| Telomere | 1 | 2019 | 36 | 0.170 |
Why?
| Tomography, X-Ray Computed | 3 | 2020 | 1161 | 0.170 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 198 | 0.170 |
Why?
| Prognosis | 2 | 2024 | 1954 | 0.170 |
Why?
| Child, Preschool | 7 | 2024 | 3883 | 0.160 |
Why?
| DNA-Binding Proteins | 3 | 2024 | 428 | 0.160 |
Why?
| Dopamine Antagonists | 1 | 2018 | 21 | 0.160 |
Why?
| Thiazoles | 1 | 2018 | 53 | 0.160 |
Why?
| Diffuse Cerebral Sclerosis of Schilder | 1 | 2018 | 8 | 0.160 |
Why?
| Amino Acyl-tRNA Synthetases | 1 | 2018 | 6 | 0.160 |
Why?
| Astrocytoma | 1 | 2018 | 20 | 0.160 |
Why?
| Paresis | 1 | 2018 | 6 | 0.160 |
Why?
| Muscular Diseases | 1 | 2018 | 61 | 0.150 |
Why?
| Meningitis, Cryptococcal | 1 | 2018 | 10 | 0.150 |
Why?
| Carcinoma | 1 | 2019 | 139 | 0.150 |
Why?
| Mitochondrial Diseases | 1 | 2018 | 42 | 0.150 |
Why?
| Pineal Gland | 1 | 2017 | 7 | 0.150 |
Why?
| Fibrous Dysplasia of Bone | 1 | 2017 | 6 | 0.150 |
Why?
| Piperazines | 1 | 2018 | 118 | 0.150 |
Why?
| Chromosomal Proteins, Non-Histone | 2 | 2024 | 40 | 0.150 |
Why?
| Status Epilepticus | 1 | 2018 | 39 | 0.150 |
Why?
| Blindness | 1 | 2017 | 31 | 0.150 |
Why?
| Orbit | 1 | 2017 | 29 | 0.150 |
Why?
| Molecular Diagnostic Techniques | 1 | 2017 | 32 | 0.150 |
Why?
| Optic Nerve Diseases | 1 | 2017 | 25 | 0.150 |
Why?
| Decompression, Surgical | 1 | 2017 | 51 | 0.150 |
Why?
| Diagnostic Errors | 1 | 2017 | 63 | 0.150 |
Why?
| Case-Control Studies | 1 | 2020 | 1126 | 0.140 |
Why?
| Neural Tube Defects | 1 | 2016 | 32 | 0.140 |
Why?
| Antigens, Neoplasm | 3 | 2008 | 152 | 0.140 |
Why?
| Cervical Vertebrae | 1 | 2017 | 58 | 0.140 |
Why?
| Social Media | 1 | 2018 | 96 | 0.140 |
Why?
| Pituitary Apoplexy | 1 | 2016 | 4 | 0.130 |
Why?
| Thoracic Neoplasms | 1 | 2016 | 13 | 0.130 |
Why?
| Pregnancy Trimester, Second | 1 | 2016 | 27 | 0.130 |
Why?
| Hypesthesia | 1 | 2016 | 17 | 0.130 |
Why?
| Epithelioid Cells | 1 | 2015 | 13 | 0.130 |
Why?
| Intracranial Hemorrhages | 1 | 2016 | 38 | 0.130 |
Why?
| Leukoencephalopathy, Progressive Multifocal | 1 | 2015 | 11 | 0.130 |
Why?
| Lymphopenia | 1 | 2015 | 18 | 0.130 |
Why?
| Plasmacytoma | 1 | 2016 | 42 | 0.130 |
Why?
| Astrocytes | 3 | 2008 | 146 | 0.130 |
Why?
| Diplopia | 1 | 2015 | 20 | 0.130 |
Why?
| Paraproteinemias | 1 | 2016 | 72 | 0.130 |
Why?
| Brain Stem | 1 | 2015 | 57 | 0.130 |
Why?
| Pituitary Gland | 1 | 2016 | 86 | 0.130 |
Why?
| Immunoglobulin Light Chains | 1 | 2016 | 82 | 0.130 |
Why?
| Cytogenetic Analysis | 1 | 2015 | 82 | 0.130 |
Why?
| Soft Tissue Neoplasms | 1 | 2015 | 57 | 0.120 |
Why?
| Epidermal Cyst | 1 | 2015 | 12 | 0.120 |
Why?
| Osteonecrosis | 1 | 2015 | 34 | 0.120 |
Why?
| Spinal Cord Diseases | 1 | 2015 | 37 | 0.120 |
Why?
| Oncogene Proteins, Fusion | 2 | 2024 | 58 | 0.120 |
Why?
| HIV Infections | 1 | 2018 | 357 | 0.120 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2015 | 164 | 0.110 |
Why?
| Seizures | 1 | 2016 | 196 | 0.110 |
Why?
| Cystadenocarcinoma, Serous | 2 | 2004 | 71 | 0.110 |
Why?
| Lung Neoplasms | 3 | 2024 | 605 | 0.110 |
Why?
| Combined Modality Therapy | 1 | 2015 | 636 | 0.110 |
Why?
| Balamuthia mandrillaris | 1 | 2012 | 2 | 0.110 |
Why?
| Receptor, erbB-2 | 2 | 2003 | 74 | 0.110 |
Why?
| Amebiasis | 1 | 2012 | 6 | 0.110 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2012 | 38 | 0.100 |
Why?
| Neurons | 2 | 2008 | 460 | 0.100 |
Why?
| Granuloma | 1 | 2012 | 44 | 0.100 |
Why?
| Biopsy, Fine-Needle | 3 | 2015 | 103 | 0.100 |
Why?
| Pregnancy Complications | 1 | 2016 | 382 | 0.100 |
Why?
| Multiple Myeloma | 2 | 2023 | 2954 | 0.090 |
Why?
| Antibodies, Monoclonal | 3 | 2003 | 460 | 0.090 |
Why?
| Chromosome Aberrations | 1 | 2012 | 297 | 0.090 |
Why?
| Spinal Neoplasms | 1 | 2010 | 29 | 0.090 |
Why?
| Uterine Cervical Neoplasms | 2 | 2003 | 276 | 0.090 |
Why?
| Gene Deletion | 1 | 2010 | 270 | 0.080 |
Why?
| Cranial Nerve Neoplasms | 1 | 2009 | 6 | 0.080 |
Why?
| Neoplasms, Multiple Primary | 1 | 2009 | 44 | 0.080 |
Why?
| Ganglia, Autonomic | 1 | 2008 | 3 | 0.080 |
Why?
| Transcriptome | 2 | 2021 | 320 | 0.080 |
Why?
| beta Catenin | 1 | 2009 | 102 | 0.080 |
Why?
| Myelin Sheath | 1 | 2008 | 28 | 0.080 |
Why?
| Fetal Death | 1 | 2008 | 23 | 0.080 |
Why?
| Spinal Cord | 1 | 2008 | 177 | 0.070 |
Why?
| Disease Progression | 2 | 2020 | 831 | 0.070 |
Why?
| Glial Fibrillary Acidic Protein | 2 | 2003 | 30 | 0.070 |
Why?
| Gestational Age | 1 | 2008 | 418 | 0.070 |
Why?
| Cytoplasm | 2 | 2004 | 91 | 0.070 |
Why?
| Cell Differentiation | 2 | 2024 | 650 | 0.070 |
Why?
| Ultrasonography, Prenatal | 1 | 2008 | 186 | 0.070 |
Why?
| Biopsy, Needle | 2 | 2004 | 181 | 0.070 |
Why?
| Gastrointestinal Stromal Tumors | 1 | 2005 | 18 | 0.070 |
Why?
| Pregnancy | 2 | 2016 | 2604 | 0.070 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2005 | 24 | 0.060 |
Why?
| Orbital Neoplasms | 1 | 2005 | 30 | 0.060 |
Why?
| Down-Regulation | 1 | 2006 | 349 | 0.060 |
Why?
| Ependyma | 1 | 2024 | 3 | 0.060 |
Why?
| Carcinoma, Small Cell | 1 | 2004 | 25 | 0.060 |
Why?
| Retrospective Studies | 3 | 2018 | 6134 | 0.060 |
Why?
| Serine Endopeptidases | 1 | 2004 | 52 | 0.060 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2004 | 59 | 0.060 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 411 | 0.050 |
Why?
| Acetic Acid | 1 | 2003 | 12 | 0.050 |
Why?
| Ovarian Neoplasms | 2 | 2004 | 447 | 0.050 |
Why?
| Cell Nucleus | 3 | 2010 | 187 | 0.050 |
Why?
| Acetates | 1 | 2003 | 49 | 0.050 |
Why?
| Ischemic Attack, Transient | 1 | 2003 | 56 | 0.050 |
Why?
| X Chromosome Inactivation | 1 | 2022 | 3 | 0.050 |
Why?
| Lymph Nodes | 1 | 2004 | 263 | 0.050 |
Why?
| Salivary Gland Neoplasms | 1 | 2002 | 7 | 0.050 |
Why?
| Cystadenocarcinoma, Papillary | 1 | 2002 | 14 | 0.050 |
Why?
| Mouth Neoplasms | 1 | 2002 | 20 | 0.050 |
Why?
| Cranial Fossa, Posterior | 1 | 2022 | 7 | 0.050 |
Why?
| Neuroglia | 1 | 2022 | 43 | 0.050 |
Why?
| Oncogene Proteins, Viral | 1 | 2002 | 52 | 0.050 |
Why?
| Janus Kinase 1 | 1 | 2021 | 17 | 0.050 |
Why?
| Cell Lineage | 1 | 2022 | 84 | 0.050 |
Why?
| Uterine Neoplasms | 1 | 2002 | 60 | 0.050 |
Why?
| Janus Kinase 2 | 1 | 2021 | 26 | 0.050 |
Why?
| Nitriles | 1 | 2021 | 54 | 0.050 |
Why?
| Germ-Line Mutation | 1 | 2021 | 61 | 0.050 |
Why?
| Prostatic Neoplasms | 1 | 2005 | 394 | 0.050 |
Why?
| Organoids | 1 | 2021 | 40 | 0.050 |
Why?
| Motor Activity | 1 | 2003 | 229 | 0.050 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 828 | 0.050 |
Why?
| Dendritic Cells | 1 | 2002 | 133 | 0.050 |
Why?
| Bone Neoplasms | 1 | 2003 | 183 | 0.050 |
Why?
| Hippocampus | 1 | 2003 | 228 | 0.050 |
Why?
| Pyrazoles | 1 | 2021 | 114 | 0.050 |
Why?
| Neoplasm Staging | 2 | 2019 | 738 | 0.050 |
Why?
| Pyrimidines | 1 | 2021 | 193 | 0.040 |
Why?
| Immunotherapy | 1 | 2002 | 240 | 0.040 |
Why?
| Neurofibrosarcoma | 1 | 2019 | 1 | 0.040 |
Why?
| Neurofibromin 1 | 1 | 2019 | 11 | 0.040 |
Why?
| Meningeal Carcinomatosis | 1 | 2019 | 6 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2004 | 1037 | 0.040 |
Why?
| Sarcoma, Myeloid | 1 | 2019 | 20 | 0.040 |
Why?
| Immunophenotyping | 1 | 2019 | 109 | 0.040 |
Why?
| Tourette Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| Creatine Kinase | 1 | 2018 | 30 | 0.040 |
Why?
| Obsessive-Compulsive Disorder | 1 | 2018 | 43 | 0.040 |
Why?
| Geography | 1 | 2018 | 60 | 0.040 |
Why?
| Adenocarcinoma | 1 | 2002 | 397 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 170 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2019 | 465 | 0.040 |
Why?
| Information Dissemination | 1 | 2018 | 79 | 0.040 |
Why?
| Muscle Fibers, Skeletal | 1 | 2018 | 62 | 0.040 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2019 | 485 | 0.030 |
Why?
| Electroencephalography | 1 | 2018 | 307 | 0.030 |
Why?
| Cardiomyopathy, Restrictive | 1 | 2016 | 5 | 0.030 |
Why?
| Optic Nerve | 1 | 2016 | 50 | 0.030 |
Why?
| Internet | 1 | 2018 | 258 | 0.030 |
Why?
| Headache | 1 | 2016 | 76 | 0.030 |
Why?
| Vision Disorders | 1 | 2016 | 57 | 0.030 |
Why?
| Hematoma | 1 | 2016 | 66 | 0.030 |
Why?
| Microsurgery | 1 | 2015 | 30 | 0.030 |
Why?
| Recurrence | 1 | 2016 | 662 | 0.030 |
Why?
| Visual Acuity | 1 | 2016 | 138 | 0.030 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2015 | 245 | 0.030 |
Why?
| Endoscopy | 1 | 2015 | 124 | 0.030 |
Why?
| Glucocorticoids | 1 | 2015 | 226 | 0.030 |
Why?
| Interleukin-2 | 2 | 2003 | 72 | 0.030 |
Why?
| Muscle, Skeletal | 1 | 2018 | 765 | 0.030 |
Why?
| Chromosomes, Human, Pair 12 | 1 | 2012 | 14 | 0.030 |
Why?
| Rats, Wistar | 2 | 2003 | 222 | 0.030 |
Why?
| Chromosomes, Human, Pair 22 | 1 | 2012 | 39 | 0.030 |
Why?
| Neurologic Examination | 1 | 2012 | 77 | 0.030 |
Why?
| Medical Records | 1 | 2012 | 83 | 0.030 |
Why?
| Steroids | 1 | 2012 | 57 | 0.030 |
Why?
| Tumor Cells, Cultured | 2 | 2003 | 468 | 0.030 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 2012 | 93 | 0.020 |
Why?
| Inflammation | 1 | 2016 | 604 | 0.020 |
Why?
| Age Factors | 1 | 2015 | 1092 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2012 | 454 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2003 | 225 | 0.020 |
Why?
| Flow Cytometry | 2 | 2003 | 476 | 0.020 |
Why?
| Neoplasm Invasiveness | 1 | 2010 | 266 | 0.020 |
Why?
| Cell Membrane | 1 | 2008 | 251 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 747 | 0.020 |
Why?
| Rats | 2 | 2003 | 3299 | 0.020 |
Why?
| Kidney | 1 | 2010 | 672 | 0.020 |
Why?
| Synaptophysin | 1 | 2005 | 7 | 0.020 |
Why?
| Neoplasms, Hormone-Dependent | 1 | 2005 | 8 | 0.020 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 22 | 0.020 |
Why?
| Epithelium | 1 | 2004 | 65 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 202 | 0.020 |
Why?
| Cytodiagnosis | 1 | 2004 | 42 | 0.010 |
Why?
| Ovary | 1 | 2004 | 115 | 0.010 |
Why?
| Eye Neoplasms | 1 | 2004 | 10 | 0.010 |
Why?
| MART-1 Antigen | 1 | 2004 | 12 | 0.010 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 1 | 2003 | 12 | 0.010 |
Why?
| Tumor Stem Cell Assay | 1 | 2003 | 17 | 0.010 |
Why?
| Lymphatic Metastasis | 1 | 2004 | 227 | 0.010 |
Why?
| Regression Analysis | 1 | 2004 | 395 | 0.010 |
Why?
| Superior Colliculi | 1 | 2003 | 5 | 0.010 |
Why?
| Antimetabolites | 1 | 2003 | 13 | 0.010 |
Why?
| Lectins | 1 | 2003 | 14 | 0.010 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2003 | 34 | 0.010 |
Why?
| Microinjections | 1 | 2003 | 32 | 0.010 |
Why?
| Endothelium | 1 | 2003 | 39 | 0.010 |
Why?
| Deoxyglucose | 1 | 2003 | 36 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 595 | 0.010 |
Why?
| Carbon Radioisotopes | 1 | 2003 | 53 | 0.010 |
Why?
| Coloring Agents | 1 | 2003 | 70 | 0.010 |
Why?
| Multivariate Analysis | 1 | 2004 | 581 | 0.010 |
Why?
| Cell Count | 1 | 2003 | 149 | 0.010 |
Why?
| Hepatocytes | 1 | 2004 | 182 | 0.010 |
Why?
| Foreign Bodies | 1 | 2003 | 65 | 0.010 |
Why?
| Tumor Virus Infections | 1 | 2002 | 42 | 0.010 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 47 | 0.010 |
Why?
| Conditioning, Operant | 1 | 2003 | 116 | 0.010 |
Why?
| Papillomaviridae | 1 | 2002 | 102 | 0.010 |
Why?
| Killer Cells, Natural | 1 | 2002 | 107 | 0.010 |
Why?
| Microglia | 1 | 2003 | 140 | 0.010 |
Why?
| Neoplasm Proteins | 1 | 2004 | 324 | 0.010 |
Why?
| Cell Division | 1 | 2002 | 295 | 0.010 |
Why?
| Cognition Disorders | 1 | 2003 | 215 | 0.010 |
Why?
| RNA, Messenger | 1 | 2004 | 1108 | 0.010 |
Why?
| Learning | 1 | 2003 | 159 | 0.010 |
Why?
| Cells, Cultured | 1 | 2004 | 1581 | 0.010 |
Why?
| Macrophages | 1 | 2003 | 363 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2004 | 1185 | 0.010 |
Why?
| Papillomavirus Infections | 1 | 2002 | 155 | 0.010 |
Why?
| Animals | 2 | 2003 | 13246 | 0.010 |
Why?
| Antineoplastic Agents | 1 | 2002 | 1186 | 0.010 |
Why?
| Breast Neoplasms | 1 | 2002 | 1179 | 0.010 |
Why?
|
|
Gokden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|